3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

113.35 +0.51 ( +0.45% ) 4:02 12/05/19 Pricing delayed 20 minutes

Volume 343,355

Recent News

See All
November 6, 2019 Nevro Reports Third Quarter 2019 Financial Results
Company Raises 2019 Guidance, Announces CFO Retirement Plans
Third Quarter 2019 and Recent Highlights
- U.S. Patient Trials and Permanent Implants Each Grew 18% Over Prior Year
- Senza® Omnia™ SCS System Commercially Launched in U.S.
- Patient Enrollment in Painful Diabetic Neuropathy RCT Completed
- Chief Commercial Officer and Chief Human Resources Officer Named
- Preliminary Injunction Against Competitor Granted Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the third quarter ended September 30, 2019. Revenue for the third quarter of 2019 was $100.2 million, a 5% increase compared to $95.6 million during the prior year period. U.S. revenue for the third quarter of 2019 was $84.2 million, a 6% increase compared to $79.6 million in the prior year period. The year-over-year increase in U.S. revenue was primarily...
November 5, 2019 Nevro Announces U.S. Launch of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain
Senza Omnia Offers Maximum Versatility by Delivering Nevro's Proprietary HF10 Therapy and All Other Available SCS Frequencies  Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for the Senza ® Omnia ™ Spinal Cord Stimulation (SCS) System. The Omnia system is the first and only SCS system designed to deliver Nevro's proprietary HF10 ® therapy in addition to all other available SCS frequencies. The Omnia system is comprised of three new components. The first is a new programmer that will make it easy for physicians to offer a wider array of waveforms across the full SCS frequency spectrum, either separately or paired together. The second element of the system is a redesigned patient remote that is smaller and more intuitive for patients to use and enhances their experience. The new remote supports greater...
October 10, 2019 ­Nevro to Report Third Quarter 2019 Financial Results
Company to Host Conference Call on Wednesday, November 6, 2019 at 1:30 p.m. PT / 4:30 p.m. ET Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the third quarter ended September 30, 2019 after the market closes on November 6, 2019. Investors interested in listening to the conference call may do so by dialing (833) 286-5807 in the U.S. or (647) 689-4452 internationally, using Conference ID: 4787437. In addition, a live webcast, as well as an archived recording, will be available on the "Investors" section of the Company's website at: www.nevro.com. About Nevro Corp.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, Senza II, Senza Omnia, HF10, More, Nevro, Nevrocloud, Surpass and the Nevro, HF10, and Frequency Pairing Logos are trademarks of Nevro Corp.